The data underlying the study has been deposited into Figshare and can be accessed there under the DOI 10.6084/m9.figshare.9955268.

Introduction {#sec005}
============

In the United States, hundreds of thousands of craniotomies are performed every year.\[[@pone.0224016.ref001]\] Patients often develop markedly elevated intraoperative serum lactate levels, though the reason for this is not entirely understood.\[[@pone.0224016.ref002],[@pone.0224016.ref003]\] Lactate, a substrate of carbohydrate metabolism, is formed from pyruvate during glycolysis. Its production reflects the magnitude of anaerobic metabolism that is related to cellular hypoxia\[[@pone.0224016.ref004],[@pone.0224016.ref005]\] and it is encountered in a multitude of clinical presentations and disease states.\[[@pone.0224016.ref006]\] Elevated lactate levels have been closely related to poor outcomes in critically ill septic shock patients,\[[@pone.0224016.ref007]--[@pone.0224016.ref010]\] as well as patients undergoing abdominal\[[@pone.0224016.ref011]\] and cardiac surgeries.\[[@pone.0224016.ref012],[@pone.0224016.ref013]\]

The etiology and clinical importance of elevated lactate during craniotomy can be difficult to determine. Patients undergoing craniotomy are at risk for developing systemic end-organ hypoperfusion secondary to fluid under resuscitation, hemorrhage, comorbid medical conditions (sepsis, congestive heart failure), or a combination of these factors. However, in some cases, elevated serum lactate could reflect localized changes in cerebral metabolism caused by perturbations such as brain retraction and tumor burden.\[[@pone.0224016.ref004],[@pone.0224016.ref014],[@pone.0224016.ref015]\] Deciding whether hyperlactatemia is due primarily to systemic versus local factors is essential because the management strategies differ. More important, however, is determining whether hyperlactatemia is associated with clinically significant patient outcomes in this patient population. This would help determine whether rising lactate values on intraoperative blood gas analysis are worth attempting to treat.

To assess the clinical significance of elevated serum lactate in the craniotomy population, our group previously performed a retrospective study comparing outcomes between those with and without elevated intraoperative serum lactate.\[[@pone.0224016.ref003]\] Elevated intraoperative serum lactate was associated with an increased risk of developing a new postoperative neurological deficit and longer length of hospital stay, but not an increased risk of renal failure, myocardial infarction, or mortality. In order to validate the findings from our previous report, we performed a prospective study. We hypothesized that in the craniotomy population, serum lactate is a marker of early regional hypoperfusion confined to the brain and that elevated intraoperative levels are associated with the development of new neurological deficits and longer hospital length of stay, but not associated with end-organ events such as myocardial infarction, renal failure or mortality. If elevated intraoperative serum lactate is associated with new neurologic deficit then rising serum lactate should be actionable, or at least serve as a warning sign for impending poor neurologic outcome.

Materials and methods {#sec006}
=====================

Following approval by the Institutional Review Board of Mount Sinai Hospital (IRB-17-01480), informed consent was obtained from eligible patients between May 2017 and July 2018 at The Mount Sinai Hospital, New York, NY. Craniotomy cases were identified from the electronic operating room schedule prior to the day of surgery. We reviewed the patient's electronic medical record (Epic Systems, Verona, WI) for inclusion and exclusion criteria, and interviewed the patient for confirmation. Inclusion criteria were: adult, English-speaking, and scheduled to undergo elective craniotomy for a brain mass or lesion involving the cranial nerves, neuroendocrine system, neurovascular system or dural-meningeal system. Exclusion criteria included cerebrospinal fluid shunt procedures, deep brain stimulation, reoperations during the same hospital admission, and cognitive impairment precluding consent. Patients with comorbid conditions that might cause increased lactate levels including pre-existing severe liver or kidney disease and sepsis were also excluded.

Preoperative data collected included date of service, age, gender, race, ethnicity, height, weight, BMI, ASA Physical Status Classification (as assigned by the anesthesiologist performing the case), preoperative diagnosis, anatomical location of the lesion, medical comorbidities (cardiovascular, respiratory, and other), baseline creatinine and presence or absence of pre-operative neurologic deficit.

Anesthesiologists were given minimal instructions other than to avoid the use of Lactated Ringer's for intravenous fluids as this could hypothetically confound lactate measurements. As per our institutional standard of care for craniotomy, anesthesiologists placed arterial lines in all patients prior to procedure start. Arterial blood gas samples including lactate levels were obtained by the anesthesiologists from the arterial line at three different points during the procedure: 1) baseline prior to craniotomy, 2) after craniotomy during surgical manipulation of the brain, and 3) during surgical closure. All arterial blood gas values were measured on GEMSTAT 3000 Premier (Instrumentation Laboratories, Bedford, MA). Patients were required to have these three arterial blood gas values at minimum; however, anesthesiologists were free to draw additional arterial blood gas values at their discretion. Elevated lactate was defined as any value greater than or equal to 2 mmol/L based on the upper limit of normal for our institution's laboratory and on review of cardiac and general surgery literature. Other intraoperative data collected included procedure, positioning, total intravenous fluids, blood products, estimated blood loss, urine output, mannitol administration (or not), total surgical time, and whether or not the patient was extubated at the end of the procedure.

The primary outcome of new neurological deficit was assessed at two time points: 1) by neurosurgical house staff approximately 6 hours postoperatively in accordance with their usual postsurgical neurologic assessment timeline and 2) at the patient's follow up visit with their neurosurgeon approximately 2 weeks postoperatively. A complete neurological examination was performed by neurosurgeons to isolate postoperative neurologic changes. This included the absence or presence of disorientation, dysarthria, aphasia, motor weakness, hemiplegia, dysmetria, pronator drift, sensory deficits, anisocoria, abnormal eye movements, facial droop, tongue deviation, hearing deficit, visual acuity or field deficit, facial sensory deficit/alteration, or events such as seizures or autonomic dysfunction.

Secondary outcomes were assessed through collection of immediate postoperative lactate, immediate postoperative troponin, immediate postoperative creatinine, 12--24 hour postoperative lactate, 12--24 hour postoperative creatinine, hospital length of stay, in-hospital mortality, and 30 day postsurgical mortality by chart review. All data were entered into a Research Electronic Data Capture tool (REDCap; Vanderbilt University, Nashville, TN) for data analysis.

Sample size calculation {#sec007}
-----------------------

In our previously published retrospective study, new neurological deficit rates were 7.3% and 14.7% for patients with normal and elevated lactate respectively. The prevalence of elevated lactate was 48%. We estimated that a two group continuity corrected chi-squared test with a 0.05 two-sided significance level would have 80% power to detect a difference in neurologic deficit between patients with and without elevated lactate with sample sizes of 323 and 294 respectively yielding a total sample size of 617. The planned study period was two years and interim analysis was performed one year into the study. The rates of new neurological deficit were 30% (15/50) and 37.5% (9/24), respectively, for patients with normal and elevated lactate. The difference in new neurological deficit between patients with normal and elevated lactate was unlikely to reach statistical significance (futility index 0.16) within our planned study period. The decision was then made to terminate patient enrollment (conditional power calculation based on PASS v 12.0.2, NCSS, LLC).

Statistical analysis {#sec008}
--------------------

Descriptive statistics are presented as mean (SD), median \[quartile 1 to quartile 3\], or N (%), as appropriate. Comparisons of outcomes (neurological deficit, in-hospital or 30-day mortality) by serum lactate condition (elevated or normal) were performed using chi-squared, Fisher-exact, 2-sample t, and Wilcoxon rank-sum tests where appropriate. Logistic regression modeling was used with backward selection (stay criterion of 0.1) to identify predictors of new postoperative neurologic deficit. Cox modeling was used to model time to hospital discharge with backward selection (stay criterion 0.1). Initially, we adjusted both models for gender, surgical time, ASA classification, BMI, age, presence of pre-operative neurologic deficit, intraoperative lactate ≥2, and preoperative diagnosis (infratentorial or supratentorial lesion). The only outcome that was investigated in the interim analysis was new neurologic deficit. We did not further adjust for its p-value in the final analysis, as it does not change the conclusion of the finding. Analyses were completed using SAS software 9.4 (SAS Institute).

Results {#sec009}
=======

A total of 85 patients were enrolled over the study period (May 2017-July 2018). Three patients were excluded due to missing intraoperative lactate values, and one patient was excluded due to surgery cancellation prior to induction of anesthesia ([Fig 1](#pone.0224016.g001){ref-type="fig"}).

![Flow diagram.\
Flow diagram of enrolled, excluded and included patients.](pone.0224016.g001){#pone.0224016.g001}

[Table 1](#pone.0224016.t001){ref-type="table"} shows the baseline characteristics of the patient cohort, both with and without elevated lactate. There was no significant difference between patients with and without elevated intraoperative lactate with regard to age, gender, race, ethnicity, ASA physical status classification, BMI, location of procedure (supratentorial versus infratentorial), comorbidities, or the presence of preoperative neurologic deficit. Patients with elevated lactate received more IV fluids intraoperatively and had greater estimated blood loss, without significant differences in blood products, urine output, total surgical time, mannitol administration, or extubation status.

10.1371/journal.pone.0224016.t001

###### Characteristics of patient cohort, grouped by level of maximum intraoperative serum lactate measurement.

![](pone.0224016.t001){#pone.0224016.t001g}

  Variable                           Overall             Max lactate \< 2 (N = 55)   Max lactate ≥ 2 (N = 26)   *P*
  ---------------------------------- ------------------- --------------------------- -------------------------- -----------
  Age                                50.6 (14.0)         51.6 (13.6)                 48.5 (14.9)                0.36
  Gender                                                                                                        0.28
  Male                               46 (56.8)           29 (52.7)                   17 (65.4)                  
  Female                             35 (43.2)           26 (47.3)                   9 (34.6)                   
  Race                                                                                                          0.41
  American Indian/Alaska Native      0                   0                           0                          
  Asian                              8 (9.9)             7 (12.7)                    1 (3.9)                    
  Native Hawaiian/Pacific Islander   0                   0                           0                          
  Black or African American          14 (17.3)           11 (20)                     3 (11.5)                   
  White                              55 (67.9)           34 (61.8)                   21 (80.8)                  
  Unknown                            4 (4.9)             3 (5.5)                     1 (3.8)                    
  Ethnicity                                                                                                     0.67
  Hispanic or Latino                 13 (16)             8 (14.6)                    5 (19.2)                   
  Not Hispanic or Latino             66 (81.5)           46 (83.6)                   20 (76.9)                  
  Unknown                            2 (2.5)             1 (1.8)                     1 (3.8)                    
  ASA PS                                                                                                        0.61
  1--2                               28 (34.6)           21 (38.2)                   7 (26.9)                   
  3                                  49 (60.5)           31 (56.4)                   18 (69.2)                  
  4                                  4 (4.9)             3 (5.4)                     1 (3.8)                    
  BMI                                27.3 (6.2)          27.4 (6.6)                  27.1 (5.3)                 0.82
  Location of lesion                                                                                            0.64
  Supratentorial                     50 (61.7)           33 (60)                     17 (65.4)                  
  Infratentorial                     31 (38.3)           22 (40)                     9 (34.6)                   
  Cardiovascular disease                                                                                        
  Hypertension                       32 (39.5)           22 (40)                     10 (38.5)                  0.90
  CAD                                3 (3.7)             3 (5.4)                     0                          0.55
  CHF                                0                   0                           0                          
  Other                              53 (65.4)           37 (67.3)                   16 (61.5)                  0.61
  Respiratory disease                                                                                           
  Asthma                             8 (9.9)             6 (10.9)                    2 (7.7)                    1.00
  COPD                               4 (4.9)             2 (3.6)                     2 (7.7)                    0.59
  Sleep apnea                        6 (7.4)             4 (7.3)                     2 (7.7)                    1.00
  Other                              67 (82.7)           46 (83.6)                   21 (80.8)                  0.76
  Other PMH:                                                                                                    
  Diabetes                           11 (13.6)           10 (18.2)                   1 (3.8)                    0.10
  Renal                              1 (1.2)             0                           1 (3.8)                    0.32
  Hepatic                            4 (4.9)             2 (3.6)                     2 (7.7)                    0.59
  Other                              72 (88.9)           48 (87.3)                   24 (92.3)                  0.71
  Pre-op neuro deficit present?                                                                                 0.10
  Yes                                59 (72.8)           37 (67.3)                   22 (84.6)                  
  No                                 22 (27.2)           18 (32.7)                   4 (15.4)                   
  Total IV fluids                    2300 (1700--3200)   2000 (1500--2500)           3125 (2000--4000)          **0.006**
  Total blood products               0 (0--0)            0 (0--0)                    0 (0--0)                   0.14
  Total EBL                          150 (100--250)      150 (100--200)              200 (150--400)             **0.012**
  Total urine output                 1775 (1200--2300)   1700 (1100--2200)           2050 (1350--2900)          0.07
  Mannitol given (y/n)               75 (92.6)           51 (92.7)                   24 (92.3)                  1.00
  Total surgical time (min)          223 (167--306)      217 (162--282)              258 (172--417)             0.17
  Patient extubated end of case                                                                                 0.20
  Yes                                74 (91.4)           52 (94.6)                   22 (84.6)                  
  No                                 7 (8.6)             3 (5.4)                     4 (15.4)                   

Note: Continuous variables are given mean (SD) with t test or median (Q1-Q3) with Wilcoxon rank test. Categorical variables are given N (col%) with chi-square test.

[Table 2](#pone.0224016.t002){ref-type="table"} compares postoperative outcomes in patients with and without elevated intraoperative lactate. No patient had evidence of postoperative myocardial infarction or renal failure and there were no mortalities within 30 days of surgery. There was no statistically significant difference in the incidence of new neurologic deficits in patients with or without elevated lactate (10/26, 38.5% vs. 15/55 27.3%, p = 0.31). Patients with a new neurologic deficit had a median of the average intraoperative lactate of 1.27 \[IQR 1.0--1.9\], compared to patients without a new neurologic deficit 1.08 \[IQR 0.85--1.70\] p = 0.39. Median length of stay was significantly longer in patients with elevated intraoperative lactate versus without elevated lactate (6.5 vs. 3 days, p = 0.003).

10.1371/journal.pone.0224016.t002

###### Postoperative outcomes with and without elevated intraoperative serum lactate.

![](pone.0224016.t002){#pone.0224016.t002g}

  Outcome                                      N[\*](#t002fn002){ref-type="table-fn"}   Overall     Max lactate \< 2 (N = 55)   Max lactate ≥ 2 (N = 26)   *P*
  -------------------------------------------- ---------------------------------------- ----------- --------------------------- -------------------------- -------------
  Postoperative troponin \> 0.05 ng/mL         75                                       0           0                           0                          
  Postoperative creatinine \> 1.10 mg/dL                                                                                                                   
  Immediate post op                            81                                       3 (3.7)     2 (3.6)                     1 (3.8)                    1.00
  12--24 hours post op                         77                                       3 (3.9)     2 (3.9)                     1 (3.8)                    1.00
  Postoperative lactate ≥2                                                                                                                                 
  Immediate postoperative                      78                                       45 (57.7)   22 (42.3)                   23 (88.5)                  **\<0.001**
  12--24 hours postoperative                   68                                       38 (55.9)   21 (45.7)                   17 (77.3)                  **0.01**
  Immediate postoperative neuro deficit        81                                                                                                          0.55
  Yes                                                                                   35 (43.2)   25 (45.5)                   10 (38.5)                  
  No                                                                                    46 (56.8)   30 (54.5)                   16 (61.5)                  
  Hospital length of stay                      81                                       4 (3--7)    3 (3--6)                    6.5 (3--7)                 **0.003**
  New neurologic deficit at 2 week follow up   81                                                                                                          **0.309**
  Yes                                                                                   25 (30.9)   15 (27.3)                   10 (38.5)                  
  No                                                                                    56 (69.1)   40 (72.7)                   16 (61.5)                  
  30 day mortality                             81                                       0           0                           0                          

Note: Continuous variables are given mean (SD) with t test or median (Q1-Q3) with Wilcoxon rank test. Categorical variables are given N(col%) with chi-square test.

\* ^=^ number of patients with available data.

Next, possible predictors of new neurologic deficit including age, gender, BMI, ASA classification, length of surgery, estimated blood loss, preoperative diagnosis (location of lesion), and presence or absence of preoperative neurologic deficit were examined using logistic regression analysis ([Table 3](#pone.0224016.t003){ref-type="table"}). Elevated intraoperative serum lactate was not found to be an independent predictor of postoperative neurologic deficit in this model (p = 0.23). The only variable found with a trend toward significance for new postoperative neurologic deficit was location of the lesion; the odds of new deficit in patients with infratentorial lesions was 2.5 times that of patients with supratentorial lesions (95% CI: 0.94--6.64; p = 0.067).

10.1371/journal.pone.0224016.t003

###### Logistic model of factors associated with new neurological deficit.

![](pone.0224016.t003){#pone.0224016.t003g}

  Factor                                    Odds Ratio   95% Confidence Interval   *P*
  ----------------------------------------- ------------ ------------------------- ------
  Age (y)                                                                          0.51
  Female                                                                           0.20
  BMI (kg/m^2^)                                                                    0.97
  ASA Classification                                                               0.90
  Preoperative neurologic deficit present                                          0.34
  Surgical time                                                                    0.99
  Infratentorial craniotomy                 2.495        0.937--6.664              0.07
  EBL                                                                              0.54
  Lactate ≥ 2 mmol/L                                                               0.23

Lastly, length of stay was modeled using Cox proportional hazards modeling ([Table 4](#pone.0224016.t004){ref-type="table"}). Variables included were the same as in [Table 3](#pone.0224016.t003){ref-type="table"}. Predictors associated with hospital length of stay were BMI and intraoperative lactate ≥2. Patients with higher BMI were more likely to be discharged sooner (relative discharge probability 1.08; CI 1.05--1.13; p \<0.001). Patients with elevated intraoperative lactate were less likely to be discharged (relative discharge probability 0.59; 95% CI 0.37--0.97; p = 0.036).

10.1371/journal.pone.0224016.t004

###### Survival model of hospital length of stay (days).

![](pone.0224016.t004){#pone.0224016.t004g}

  Factor                                    Hazard Ratio   95% Confidence Interval   *P*
  ----------------------------------------- -------------- ------------------------- -------------
  Age (y)                                                                            0.90
  Female                                                                             0.53
  BMI (kg/m^2^)                             1.084          1.045--1.125              **\<0.001**
  ASA Classification                                                                 0.29
  Preoperative neurologic deficit present                                            0.90
  Surgical time                                                                      1.16
  Infratentorial craniotomy                                                          0.99
  EBL                                                                                0.44
  Lactate ≥ 2 mmol/L                        0.594          0.365--0.966              **0.04**

Discussion {#sec010}
==========

We found that patients with and without elevated lactate had no difference in the incidence of new neurologic deficit 2 weeks postoperatively. Differences between the groups included longer length of stay in the elevated lactate group, with elevated lactate as a predictor of lengthened hospital stay.

Longer hospital stay in those with elevated intraoperative lactates is a finding consistent with our retrospective study.\[[@pone.0224016.ref003]\] While the two groups were similar in medical comorbidities, it is possible that elevated lactate may be a sign of systemic hypoperfusion in cases that involved fluid shifts and/or changes in perfusion. Furthermore, logistic regression analysis revealed elevated lactate to predict longer length of stay. Reasons for this are not readily apparent, however there may be postoperative variables other than a neurologic deficit that could possibly explain this, such as infection, DVT, subclinical cerebral ischemia that would manifest as diffusion restriction on post-operative MRI, or other reasons that could be measured in future studies to validate or better explain this association.

Our results differ from our retrospective study with regard to the finding of new neurologic deficit.\[[@pone.0224016.ref003]\] It is possible that prospective screening for new neurologic deficits using certain specific criteria yielded different results than retrospective chart review. Assessment of neurologic status in the current study is more comprehensive than in the retrospective study\[[@pone.0224016.ref003]\], with assessments being performed at standardized time intervals and using certain common deficits as delineated to us by our neurosurgical colleagues (KY). Next, our current study recruited outpatient elective craniotomy patients whereas the previous study sample was found by CPT code for craniotomy and may have included a wider variety of patients, such as inpatients, emergency surgeries, patients with altered mental status, and moribund patients that would have been excluded from the current study. Furthermore, sensitivity analysis in the retrospective study comparing patients in the study cohort to those excluded due to no lactate levels drawn revealed those patients without lactates drawn to be significantly healthier. In our current study cohort, all patients, by design, had intraoperative lactates drawn. As these were elective outpatient craniotomy cases, it is likely that the anesthesiologists may not have otherwise drawn ABGs on these patients intraoperatively, and thus a large number of this type of patient would have been excluded from the previous study. This supports that the study populations were likely somewhat different between the two studies and may have led to the difference in the finding of new neurologic deficit.

One reason that we may not have found a difference between groups with regard to new neurologic deficit is that the contribution of surgical manipulation to overall systemic lactate levels may not be measurable. Other studies have used microdialysis catheters to study cerebral metabolites in patients undergoing meningioma resections and found that certain metabolites, namely lactate, pyruvate, and glucose, can change with the use of temporary arterial occlusion for proximal control during intracranial aneurysm surgery. One study found that a higher pyruvate: lactate ratio postoperatively was associated with unfavorable outcomes in patients.\[[@pone.0224016.ref016]\] Whether or not the lactate found in cerebral microdialysis catheters can be extrapolated to serum lactate remains to be seen. On the other hand, transcranial magnetic stimulation of the brain has been shown to increase serum lactate lending support to the notion that brain lactate production may indeed be linked to that of the serum. \[[@pone.0224016.ref017]\] Along similar lines, studies have suggested cerebral hyperlactatemia as a potential biomarker for malignancy of brain tumors.\[[@pone.0224016.ref014],[@pone.0224016.ref015]\]

Studies have pointed to the questionable clinical importance of elevated serum lactate in neurosurgical patients. One such study examined postoperative serum lactate levels in a neurosurgical ICU including brain tumor, spinal surgery and non-neurosurgical patients and found higher serum lactate levels in brain tumor and spinal surgery patients compared to non-neurosurgical patients. The primary outcome was mortality and the lactates were obtained postoperatively rather than intraoperatively. They found that elevated serum lactate was not associated with mortality.\[[@pone.0224016.ref002]\] Other studies have shown elevated serum lactate levels both preoperatively and intraoperatively not to be associated with mortality in patients undergoing craniotomies or craniectomies.\[[@pone.0224016.ref018],[@pone.0224016.ref019]\] Elevated serum lactate levels have also been attributed to administration of furosemide with mannitol which is common in neurosurgery.\[[@pone.0224016.ref020]\] Additionally, in both our current and previous study, no patient had evidence of postoperative end-organ dysfunction such as MI, renal failure or death within 30 days of surgery. In the current study, given the small number of patients enrolled and that catastrophic outcomes such as mortality and end organ dysfunction were relatively rare, this particular result is expected.

Interestingly, in contrast to the association of lactate with unfavorable outcome, there is a growing body of literature regarding lactate as protective or beneficial in brain injury. Studies have postulated that during brain stress the body may release stores of lactate to feed into the TCA cycle of neurons (the astrocyte-neuron lactate shuttle hypothesis).\[[@pone.0224016.ref021]\] Brain uptake of systemic lactate "may reflect an adaptive response to the increased energy demands and change in metabolic priorities of the injured brain."\[[@pone.0224016.ref021]\] Endogenous lactate use by the injured brain implies that administering lactate to traumatic brain injury patients could be advantageous, and studies of rats given intravenous lactate after fluid percussion injury to the brain actually performed better than those given saline.\[[@pone.0224016.ref022],[@pone.0224016.ref023]\] This brings up a provocative question--Is the lactate routinely measured intraoperatively during brain surgery coming from the brain due to surgical manipulation, or is it instead being mobilized from the body to serve the brain for assistance with the injury/stress of surgery?

In our study we observed a trend that patients with infratentorial lesions were 2.5 times more likely to have a new postoperative neurologic deficit than patients with supratentorial lesions (p = 0.067). One other study found that due to the anatomical vicinity to delicate brain structures and the relatively narrower surgical corridors employed during posterior fossa surgery, arteriovenous malformations in the infratentorial region are more hazardous and prone to rupture leading to worse neurological outcome compared to those that were supratentorial.\[[@pone.0224016.ref024]\] We did not separate our findings by type of surgery; however, it is clear that further research is needed to elucidate whether location of the lesion is associated with new neurologic deficit.

In this cohort, patients with higher BMI were more likely to be discharged sooner (relative discharge probability 1.08). Overall our patient population had a median BMI of 27.3 with a standard deviation of 6.2. One possible explanation for the findings regarding BMI is that the lower BMI patients were either frail or cachectic (possibly due to malignancy) and might have had less physiologic reserve and required greater recuperation time post surgically whereas a normal or slightly elevated BMI may have been protective, giving the patient higher likelihood of early hospital discharge. The "obesity paradox" suggests that, counterintuitively, excess body weight may be protective and associated with improved outcomes in certain groups. Studies have confirmed the presence of this paradox in patients with neurologic injury. Specifically, studies of patients with ischemic and hemorrhagic stroke showed overweight or mildly obese status conferred greater survival.\[[@pone.0224016.ref025],[@pone.0224016.ref026]\] While these studies focused on stroke patients rather than post-surgical patients, at least one study showed shorter hospital length of stay in patients with higher BMI.\[[@pone.0224016.ref027]\]

Lastly, similar to our previous study, patients with elevated serum lactate received more intravenous fluids intraoperatively than their normal lactate counterparts (3125mL vs 2000mL; p = 0.006). This suggests that anesthesiologists tended to respond to or attempt to "treat" rising lactate by administering additional fluids. It is possible that the elevated lactate may have been due to under-resuscitation or cerebral hypoperfusion, the former but not the latter being corrected by additional fluid administration. This being said, neither systemic nor local hypoperfusion intraoperatively was associated with new postoperative neurologic deficits. Thus, one may speculate that it was likely temporary and/or reversible, and that the elevated lactate was not an important marker of impending poor neurologic outcome.

The major limitation of this study is that the study was terminated early due to high futility index in interim analysis. Although a small increase in the rate of new neurologic deficit was seen in patients with elevated lactate, this study did not demonstrate a clinically significant difference between the two groups. Future prospective studies with larger sample size could eliminate the possibility of a beta error. Similar to our retrospective study\[[@pone.0224016.ref003]\], we used systemic markers such as serum lactate without correlation to direct measures of cerebral perfusion such as use of jugular bulb sampling. Similarly, data such as cerebral blood flow or NIRS measurements were not available.

Conclusions {#sec011}
===========

In conclusion, in this prospective study of patients undergoing craniotomy, we sought to determine whether elevated lactate in craniotomy patients was associated with neurologic as well as systemic complications. On interim analysis, elevated intraoperative lactate level was not independently associated with new postoperative neurologic deficits, renal failure, myocardial infarction, or 30 day mortality. Patients with elevated lactate had significantly longer hospital admissions, with the potential for increased hospital costs. The difference in incidence of new neurologic deficit between patients with and without elevated intraoperative serum lactate was small, with a high futility index thus enrollment was terminated. While this study includes a relatively small number of patients, the results indicate that serum lactate is unlikely to be a marker of poor neurologic outcome and isolated hyperlactatemia (without signs of systemic compromise such as bleeding, etc.) might not be a cause for alarm when encountered intraoperatively in craniotomy patients. Future, larger-scale prospective studies can focus on different markers such as cerebral lactate or other measures of cerebral perfusion and assess whether these are of more value to intraoperative anesthetic and surgical decision making.

10.1371/journal.pone.0224016.r001
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4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Romano et al present a prospective cohort analysis of the role serum lactate in craniotomy patients. This is a well written well designed study that is a continuation of their previous retrospective analysis. Listed below are some constructive suggestions.

1\. Would like to see a few paragraphs describing how the prospective analysis design compares to the retrospective analysis. In the prospective design there appears to be a defined regimen in terms of frequency of ABG, tropinin and creatinine draws, neuro checks, and details of the neuro exam. But in a retrospective review it is common to find out certain regimens may not have been instituted. For instance, it appears that in the retrospective patients there may have been a lack of consistency in the frequency of ABG draws. I would like to know what were the limitations of the retrospective design and how that could have led to different findings between the retrospective and prospective studies.

2\. Would like an explanation on why base deficit or base excess results were not presented. Would like a commentary on whether or not base deficit measurement would represent a good correlate or surrogate marker in relation to lactate for brain perfusion and end organ tissue perfusion. Also further commentary on administering albumin vs lactated ringers vs normal saline on their effects on lactate, base deficit and tissue oxygenation.

3\. The authors also commented on the role of microdialysis in meningioma patients. Will there be future research plans to compare serum lactate in relation to cerebral microdialysis glucose and lactate/pyruvate ratios (Carteron et al, Front Neurol. 2017; 8: 601). Also would like to have commentary on how serum or cerebral lactate could differ in the setting of craniotomy for tumor excision vs craniotomy/embolization of neurovascular lesions (aneurysms, avm)

Reviewer \#2: Rosenberger Review: Manuscript PONE-D-19-23758

1\. What are the main claims of the paper and how significant are they for the discipline?

→ Main purpose of the paper was to identify the significance of hyperlactatemia during craniotomy in regards to postoperative morbidity and mortality in a prospective randomized trial and also its critical differential diagnosis for the clinican

2\. Are the claims properly placed in the context of the previous literature? Have the authors treated the literature fairly?

→ Literature was treated fairly. The authors published a retrospective study showing clinical significance of intraoperative hyperlactatemia for postoperative outcome and therefore decided to follow up with a prospective trial

3\. Do the data and analyses fully support the claims? If not, what other evidence is required?

→ Data analyses revealed no significant impact on patient outcome after study was terminated early for high futility index in interim analysis.

4\. PLOS ONE encourages authors to publish detailed protocols and algorithms as supporting information online. Do any particular methods used in the manuscript warrant such treatment? If a protocol is already provided, for example for a randomized controlled trial, are there any important deviations from it? If so, have the authors explained adequately why the deviations occurred?

→ Authors did follow a detailed protocol, all methods were addressed, no deviations apparent for reviewer. The study was terminated early due to high futility index in interim analysis.

5\. If the paper is considered unsuitable for publication in its present form, does the study itself show sufficient potential that the authors should be encouraged to resubmit a revised version?

→ I recommend considering a publication in the current format based on the fact that the authors published a retrospective study and followed scientific principles to validate their previously published retrospective results with a prospective trial. The discussion includes reasons why retrospective results differ from the prospective study results and this message is important to be shared. It allows the reader to critically review results published based on retrospective data analysis versus prospective analysis - and how it can change clinical practice management if data is based on retrospective data only. The discussion also addresses the difference of serum lactate as a biomarker in neurosurgical patients versus the understanding and differential diagnosis of elevated serum lactate in the general critical care patient population. This is of value for critical care and non-critical care specialists.

6\. Are original data deposited in appropriate repositories and accession/version numbers provided for genes, proteins, mutants, diseases, etc.?

→ Yes

7\. Are details of the methodology sufficient to allow the experiments to be reproduced?

→ Yes

8\. Is the manuscript well organized and written clearly enough to be accessible to non-specialists?

→ Yes. I do compliment the research team for their candid data review. Thorough analysis of their own data from a retrospective study going forward to prospectively validate the results and critically assess further hypothesis why the current hypothesis of hyperlactatemia in craniotomy did not impact neurologic outcome is in clear and concise form, and accessible to non-specialists.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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